ABSTRACT

Objective: To compare the cost of adverse events (AEs) associated with preventive treatment of migraine with fremanezumab, versus erenumab, galcanezumab, and onabotulinumtoxinA.

Methods: A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, with 1,000 simulations, in patients with at least 4 days of migraine per month, from the perspective of the National Health System and a time horizon of 12 weeks. The frequency of AEs described in the clinical trials was analyzed with 12 weeks of treatment. Unit costs (€) of management of AEs were obtained from public health prices, expert panels, and published Spanish studies.

Results: Fremanezumab would generate average savings of -€469 (95% CI -€303; -€674) versus erenumab, -€268 (95% CI -€171; -€391) versus galcanezumab, -€1,100 (95% CI -€704; -€1,608) or -€1,295 (95% CI -€835; -€1,893) versus onabotulinumtoxinA using real-life or clinical trial data, respectively.

Conclusions: The different safety profile of treatment with fremanezumab, compared to erenumab, galcanezumab, and onabotulinumtoxinA, would generate savings in health-care resources in all the scenarios considered.

摘要

目的：比较与弗雷曼单抗，依那单抗，加那珠单抗和onabotulinumtoxinA预防性治疗偏头痛相关的不良事件（AEs）的费用。

方法：从国家卫生系统的角度和12周的时间范围内，对每月至少偏头痛4天的患者，使用二阶蒙特卡洛模拟和1000次模拟进行了概率模型分析。经过12周的治疗，对临床试验中描述的AE发生频率进行了分析。不良事件管理的单位成本（€）来自公共卫生价格，专家小组和已发表的西班牙研究。

结果：与erenumab相比，Fremanezumab的平均节省为-€469（95％CI-€303;-€674），与galcanezumab相比则为-€268（95％CI-€171;-€391），-€1,100（95％） CI-€704;-€1,608）或-€1,295（95％CI-€835;-€1,893）分别与真实肉毒杆菌毒素A或临床试验数据比较。

结论：与艾瑞单抗，加仑单抗和onabotulinumtoxinA相比，使用fremanezumab治疗的不同安全性将在所有考虑的情况下节省医疗资源。